Metabolic and Cardiovascular Disorders Development Pipeline

Metabolic and Heart Disease Drug Pipeline and Clinical Trials

Pfizer's mission is to deliver medicines that make a real difference in quality of life for patients with metabolic diseases and at cardiovascular risk. Scientists in our research and development (R&D) programs are committed to speeding the delivery of new treatments. We pledge to maintain the safety of patients who take part in our trials and to uphold the highest ethical standards in all of our research initiatives.

On this page, you will find more information about our pipeline, which investigational therapies are under development, and in which stages.

 

Internal Medicine Pipeline & Trials

Internal Medicine Pipeline as of July 28, 2021

  • Discovery Projects
  • Phase 1
    6
  • Phase 2
    5
  • Phase 3
    3
  • Registration
    1
  • Total15
Submission Type
Compound Type
Phase of Development
Compound NameIndicationPhaseSubmission TypeCompound Type
tanezumab
Therapeutic Area:
Internal Medicine
Phase:Registration
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Nerve Growth Factor Inhibitor
Go to clinical trial
Chronic Pain due to Moderate-to-Severe Osteoarthritis (OA) (Biologic) (U.S., E.U.) Registration New Molecular Entity Biologic
relugolix fixed dose combination
Therapeutic Area:
Internal Medicine
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
Oral GnRH receptor antagonist
Go to clinical trial
Combination with estradiol and norethindrone acetate for Endometriosis Phase 3 Product Enhancement Small Molecule
tanezumab
Therapeutic Area:
Internal Medicine
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Nerve Growth Factor Inhibitor
Go to clinical trial
Cancer Pain (Biologic) Phase 3 Product Enhancement Biologic
relugolix fixed dose combination
Therapeutic Area:
Internal Medicine
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
Oral GnRH receptor antagonist
Combination with estradiol and norethindrone acetate for contraceptive efficacy Phase 3 Product Enhancement Small Molecule
danuglipron (PF-06882961)
Therapeutic Area:
Internal Medicine
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Glucagon-like peptide 1 receptor (GLP-1R) Agonist
Diabetes Mellitus-Type 2 Phase 2 New Molecular Entity Small Molecule
danuglipron (PF-06882961)
Therapeutic Area:
Internal Medicine
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Glucagon-like peptide 1 receptor (GLP-1R) Agonist
Obesity Phase 2 Product Enhancement Small Molecule
PF-06865571
Therapeutic Area:
Internal Medicine
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor
Non-alcoholic Steatohepatitis (NASH) with Liver Fibrosis Phase 2 New Molecular Entity Small Molecule
vupanorsen (PF-07285557)
Therapeutic Area:
Internal Medicine
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Angiopoietin Like 3(ANGPTL3) Antisense Oligonucleotide
Severe Hypertriglyceridemia, Cardiovascular Risk Reduction Phase 2 New Molecular Entity Small Molecule
PF-05221304 + PF-06865571
Therapeutic Area:
Internal Medicine
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Acetyl CoA-Carboxylase (ACC) Inhibitor; Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor
Non-alcoholic Steatohepatitis (NASH) with Liver Fibrosis Phase 2 New Molecular Entity Small Molecule
danuglipron (PF-06882961) + PF-06865571
Therapeutic Area:
Internal Medicine
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Glucagon-like peptide 1 receptor (GLP-1R) Agonist; Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor
Non-Alcoholic Steatohepatitis (NASH) with Liver Fibrosis Phase 1 New Molecular Entity Small Molecule
PF-06842874
Therapeutic Area:
Internal Medicine
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
CDK 4,6 Inhibitor
Pulmonary Arterial Hypertension (ORPHAN - U.S.) Phase 1 New Molecular Entity Small Molecule
PF-06946860
Therapeutic Area:
Internal Medicine
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
Growth Differentiation Factor 15 (GDF15) Monoclonal Antibody
Cachexia (Biologic) Phase 1 New Molecular Entity Biologic
PF-07258669
Therapeutic Area:
Internal Medicine
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Melanocortin-4 receptor (MC4R) Antagonist
Anorexia Phase 1 New Molecular Entity Small Molecule
PF-07081532
Therapeutic Area:
Internal Medicine
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Glucagon-like peptide 1 receptor (GLP-1R) Agonist
Diabetes Mellitus-Type 2 and Obesity Phase 1 New Molecular Entity Small Molecule
PF-07202954
Therapeutic Area:
Internal Medicine
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor
Non-alcoholic Steatohepatitis (NASH) with Liver Fibrosis
Project advanced
Phase 1 New Molecular Entity Small Molecule